NOS1 and schizophrenia: The stable gastric pentadecapeptide BPC 157, NO-agents, L-NAME, NO-synthase (NOS)-blocker, and L-arginine, NOS-substrate, given alone or together (triple application), known to particularly mutually interact and form particular NO-system connections (for review, see [8,9,10,11]) might result with the particular counteraction of each of the resembling “negative-like” schizophrenia symptoms (i.e., with L-NAME or L-arginine, with both or none).